KPTI vs. BTAI, CMPS, ACIU, CRBP, ALXO, TERN, ALT, SLRN, VERV, and LXRX
Should you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include BioXcel Therapeutics (BTAI), COMPASS Pathways (CMPS), AC Immune (ACIU), Corbus Pharmaceuticals (CRBP), ALX Oncology (ALXO), Terns Pharmaceuticals (TERN), Altimmune (ALT), Acelyrin (SLRN), Verve Therapeutics (VERV), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "pharmaceutical preparations" industry.
BioXcel Therapeutics (NASDAQ:BTAI) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.
BioXcel Therapeutics presently has a consensus target price of $16.71, indicating a potential upside of 1,147.33%. Karyopharm Therapeutics has a consensus target price of $4.80, indicating a potential upside of 394.85%. Given Karyopharm Therapeutics' higher probable upside, equities analysts plainly believe BioXcel Therapeutics is more favorable than Karyopharm Therapeutics.
Karyopharm Therapeutics received 289 more outperform votes than BioXcel Therapeutics when rated by MarketBeat users. Likewise, 72.09% of users gave Karyopharm Therapeutics an outperform vote while only 67.23% of users gave BioXcel Therapeutics an outperform vote.
Karyopharm Therapeutics has a net margin of -104.18% compared to Karyopharm Therapeutics' net margin of -8,715.72%. BioXcel Therapeutics' return on equity of 0.00% beat Karyopharm Therapeutics' return on equity.
In the previous week, Karyopharm Therapeutics had 15 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 19 mentions for Karyopharm Therapeutics and 4 mentions for BioXcel Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.76 beat BioXcel Therapeutics' score of -0.10 indicating that BioXcel Therapeutics is being referred to more favorably in the media.
Karyopharm Therapeutics has higher revenue and earnings than BioXcel Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 35.8% of BioXcel Therapeutics shares are held by insiders. Comparatively, 4.3% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BioXcel Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.
Summary
Karyopharm Therapeutics beats BioXcel Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Karyopharm Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Karyopharm Therapeutics Competitors List
Related Companies and Tools
